
InfuSystem Hlds (INFU) Stock Forecast & Price Target
InfuSystem Hlds (INFU) Analyst Ratings
Bulls say
InfuSystems Holdings Inc. reported a significant increase in gross profit for the quarter, rising by $2.2 million year-over-year to $20.4 million, with a gross margin expansion of approximately 260 basis points to 56.4%. The company's Patient Services segment contributed to an 8% growth in revenue, bolstered by a new contract with a large hospital system that is expected to enhance patient volumes. Additionally, year-to-date net operating cash flow improved to $17.3 million, reflecting a 38% increase attributed to higher earnings and improved working capital management, further underlining the company's solid financial positioning.
Bears say
InfuSystems Holdings faces a challenging financial outlook primarily due to a restructured contract with its largest biomedical services customer, which is projected to decrease annual revenue by $7.1 million in 2026 and negatively impact overall revenue estimates. Additionally, the company is experiencing margin compression and competitive pressures, compounded by potential delays in key growth drivers such as Pain Management and Wound Care, which could further hinder revenue generation and margin performance. Cash flow from operations also showed signs of decline, with a 10% year-over-year decrease in Q4, adding to concerns regarding the company’s financial stability and growth trajectory.
This aggregate rating is based on analysts' research of InfuSystem Hlds and is not a guaranteed prediction by Public.com or investment advice.
InfuSystem Hlds (INFU) Analyst Forecast & Price Prediction
Start investing in InfuSystem Hlds (INFU)
Order type
Buy in
Order amount
Est. shares
0 shares